VANCOUVER, Jan. 17, 2012 /CNW/ - iCo Therapeutics Inc. (TSX-V: ICO) announced today that it has retained Crescendo Communications, LLC
("Crescendo") to help broaden investor awareness with its proprietary
network of small-cap investors.
"We are pleased and excited to start working with iCo Therapeutics,
which is rapidly advancing new approaches to treating ophthalmic and
other diseases," commented David Waldman, President of Crescendo. "iCo
has built a solid reputation for developing novel reformulations of
the active ingredients in drugs that have a clear clinical benefit and
an attractive safety profile. By expanding and creating new
indications for established molecules, iCo is creating significant
value from its pipeline that can assist new patients and bring
therapies to market faster than traditional approaches. By focusing on
sight-threatening diseases, the company effectively leverages its
strong clinical expertise in ophthalmology in order to develop novel
product candidates targeting unmet medical need in ocular disease such
as diabetic macular edema (DME), the leading cause of blindness in
working age adults."
"iCo has built a robust pipeline, including the company's three lead
products: iCo-007, in Phase II for the treatment of DME; iCo-008
(Bertilimumab), a product with Phase II clinical history to be
developed for sight-threatening diseases; and an oral Amphotericin B
delivery system for life-threatening infectious diseases. iCo is
uniquely positioned to capitalize on several very attractive and
sizable end markets with an industry leading management team, board of
directors, board of advisors and strategic partners. We look forward to
working on a comprehensive investor relations program with their
current investor relations team and enhancing outreach efforts,
especially with non-sector specific investors looking for healthcare
"The team at Crescendo has extensive experience and a successful track
record of working with small-cap public companies throughout North
America," said Andrew Rae, President & CEO of iCo Therapeutics. "We are
confident that Crescendo, along with Equicom Investor Relations, will
help us proactively communicate our business model and upcoming
milestones as we move into the next stage of our development."
The agreement with Crescendo is for a one-year term that may be
terminated by either party in writing with 30 days' notice. In return
for its services, the Company will pay a consulting fee to Crescendo of
$6,000 per month plus approved expenses incurred on behalf of the
About Crescendo Communications, LLC
Crescendo Communications, LLC, headquartered in New York City with
offices in Beijing, Shanghai and Moscow, is an emerging leader within
the investor relations industry. The firm was founded on a strategic
and professional approach to investor relations that builds awareness
of public companies through tailored outreach programs that target
institutional investors, analysts, and the financial media. The firm's
approach is centered around properly educating investors and
cultivating trust in order to uphold and protect the their clients'
long-term credibility and reputation on Wall Street and within the
global capital markets.
About iCo Therapeutics
iCo Therapeutics Inc. is a Vancouver-based reprofiling company focused
on redosing or reformulating drugs with clinical history for new or
expanded indications. iCo has exclusive worldwide rights to three
products: iCo-007, in Phase 2 for the treatment of Diabetic Macular
Edema (DME), iCo-008 (Bertilimumab), a product with Phase 2 clinical
history to be developed for sight threatening diseases; and an oral
Amphotericin B delivery system for life-threatening infectious
diseases. Immune Pharmaceuticals licensed systemic rights to iCo-008 in
June 2011. iCo trades on the TSX Venture Exchange under the symbol
"ICO". For more information, visit the Company website at: www.icotherapeutics.com.
No regulatory authority has approved or disapproved the content of this
release. The TSX Venture Exchange does not accept responsibility for
the adequacy or accuracy of this release.
Forward Looking Statements
Certain statements included in this press release may be considered
forward-looking. Such statements involve known and unknown risks,
uncertainties and other factors that may cause actual results,
performance or achievements to be materially different from those
implied by such statements, and therefore these statements should not
be read as guarantees of future performance or results. All
forward-looking statements are based on iCo Therapeutics' current
beliefs as well as assumptions made by and information currently
available to iCo Therapeutics and relate to, among other things,
anticipated financial performance, business prospects, strategies,
regulatory developments, market acceptance and future commitments.
Readers are cautioned not to place undue reliance on these
forward-looking statements, which speak only as of the date of this
press release. Due to risks and uncertainties, including the risks and
uncertainties identified by iCo Therapeutics in its public securities
filings; actual events may differ materially from current expectations.
iCo Therapeutics disclaims any intention or obligation to update or
revise any forward-looking statements, whether as a result of new
information, future events or otherwise.
SOURCE iCo Therapeutics Inc.
For further information: